Research Progress of Prostate Cancer Stem Cell Inhibitors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 284
Special Issue Editor
Interests: molecular pathology; prostate cancer; genitourinary pathology; biomarkers research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer (PCa) is the second leading cause of mortality and morbidity among men worldwide. The standard care of therapy for PCa comprises chemotherapy, radiation therapy, brachytherapy, secondary hormonal and targeted therapies, and surgery, although a multitherapy approach is usually preferred in many patients depending on the disease stage. Nevertheless, castration-resistant prostate cancer (CRPC) develops due to the presence of a subpopulation of cancer stem cells (CSCs) within the tumor bulk. This instigates the development of novel therapeutic approaches using targeted therapies, including prostate cancer stem cell (PCSC) inhibitors.Targeting PCSC-related signaling pathways include inhibitors against the Hedgehog (Hh) pathways, Wnt signaling, Notch, NF-κB, and PI3K/AKT/mTOR, among other pathways. This approach in the management of PCa is the hub for “personalized medicine” in the 21st century. It is an area of great interest to physicians and researchers working in the scientific field—in particular, molecular pathologists and hematology oncologists.This Special Issue focuses on research and experiences related to PCSC targeted therapies. It will include research papers, reviews, and case reports that cover the identification of novel therapeutic targets, with a focus on the prospects for improving personalized cancer care using new technologies to enhance cancer patient diagnoses, management, and outcomes.
In this issue, we invite researchers in genitourinary pathology, hematology oncology, and other fields of cancer research to submit high-quality empirical papers or reviews related to the issues in this research area.
Dr. Hisham Bahmad
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- cancer stem cells
- inhibitors
- biomarkers
- therapeutic target
- personalized medicine
- targeted therapy
- molecular signatures
- diagnosis
- prognosis
